Exploring Non-Adherence and Disease Activity in Lupus and Ankylosing Spondylitis Treatment Outcomes

This chapter examines the effects of cost-related non-adherence in lupus, linking it to higher disease activity and damage. It also reviews a study on Jo-1 positivity in anti-synthetase syndrome and critiques a clinical trial of an IL-23 inhibitor for ankylosing spondylitis, highlighting issues with placebo response rates.